The effect of cisplatin+etoposide therapy on serum total and lipid-bound sialic acid levels in patients with non-small cell lung cancer

Basit Öğe Kaydı
dc.authorscopusid6603560194
dc.authorscopusid12243344000
dc.authorscopusid6506080738
dc.authorscopusid26767879800
dc.authorscopusid8917314800
dc.authorscopusid55882854000
dc.contributor.authorGökmen S.S.
dc.contributor.authorKazezo?lu C.
dc.contributor.authorTabako?lu E.
dc.contributor.authorGüngör O.
dc.contributor.authorAltiay G.
dc.contributor.authorTüre M.
dc.date.accessioned2024-06-12T10:29:24Z
dc.date.available2024-06-12T10:29:24Z
dc.date.issued2010
dc.description.abstractObjectives: To investigate the effect of cisplatin+etoposide therapy on serum total and lipid-bound sialic acid levels in patients with non-small cell lung cancer and evaluate the role of these parameters in the monitoring of the therapy. Patients and Methods: To 18 patients (all men) who are newly diagnosed as nons-mall cell lung cancer, cisplatin was given intravenously (80mg/m2) on day 1 and etoposide was given (100mg/m2) on day 1-3 to the patients once at an interval of 21 day. Blood samples before the first chemotherapy were compared with those obtained after the second and third chemotherapy. The percent of chemotherapy responses of patients were also calculated. Total and lipid-bound sialic levels were determined by the methods of Warren and Katopodis, respectively. Results: There was a significant decrease in serum lipid-bound sialic acid levels after the second chemotherapy when compared with those before the first chemotherapy (t=2.216, p=0.041). Positive response to cisplatin+etoposide therapy was observed in 88.89% (11.11% of total response, 44.44% of partial response and 33.33% of stable response) of the patients. Progressive disease was established in only 11.11% of the patients. It was found a statistically significant decrease in both serum total (t=2.924, p=0.017) and lipid-bound sialic acid (t=3.635, p=0.005) levels after the third chemotherapy when compared with those before the first chemotherapy. Conclusion: Determination of serum total and lipid-bound sialic acid levels besides routine applications may be useful in the monitoring of cisplatin+etoposide therapy. © TurkJBiochem.com.en_US
dc.identifier.endpage242en_US
dc.identifier.issn1303-829X
dc.identifier.issue3en_US
dc.identifier.scopus2-s2.0-78349268319en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage236en_US
dc.identifier.urihttps://hdl.handle.net/20.500.14551/17743
dc.identifier.volume35en_US
dc.indekslendigikaynakScopusen_US
dc.language.isotren_US
dc.publisherTurkish Biochemistry Societyen_US
dc.relation.ispartofTurkish Journal of Biochemistryen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectLipid-Bound Sialic Acid; Non-Small Cell Lung Cancer; Total Sialic Aciden_US
dc.subjectCisplatin; Etoposide; Sialic Acid; Article; Blood Sampling; Cancer Combination Chemotherapy; Cancer Growth; Clinical Article; Clinical Evaluation; Drug Response; Human; Lung Non Small Cell Cancer; Male; Protein Blood Level; Treatment Outcomeen_US
dc.titleThe effect of cisplatin+etoposide therapy on serum total and lipid-bound sialic acid levels in patients with non-small cell lung canceren_US
dc.title.alternativeKüçük hücreli dışı akci?er kanserli hastalarda sisplatin+etoposid tedavisinin serum total ve lipide ba?lı sialik asid düzeylerine etkisien_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu